<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479450</url>
  </required_header>
  <id_info>
    <org_study_id>surfactant for NRDS</org_study_id>
    <nct_id>NCT03479450</nct_id>
  </id_info>
  <brief_title>Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study</brief_title>
  <official_title>Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>the first people hospital of Tibet autonomous region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the second people hospital of Lasa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the first people hospital of Shigatse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the first people hospital of Lasa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the people hospital of Linzhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the people hospital of Laqu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The traditional concept believes that the etiology of neonatal respiratory distress syndrome&#xD;
      (RDS) is immature development of lung,especially the surfactant synthesis system,and RDS is&#xD;
      still one of the major causes of mortality and morbidity in newborns, especially premature&#xD;
      infants.In recent years, using pulmonary surfactant replacement therapy (PS treatment) in the&#xD;
      treatment of respiratory distress syndrome (RDS) is a major breakthrough in neonatal&#xD;
      medicine.Combined with clinical practice and experience,and through Meta analysis of related&#xD;
      randomized controlled trials (RCTs),it confirms that natural surfactant treatment can reduce&#xD;
      mortality,the incidence of pulmonary air leaks (pneumothorax and interstitial lung&#xD;
      emphysema),and the incidence of bronchopulmonary dysplasia (BPD) or 28-day-old mortality.For&#xD;
      RDS in preterm infants whose gestation is &lt;35 weeks ,surfactant replacement therapy is also&#xD;
      more effective than in nearly term and full term infants.Therefore, in the analysis of cases&#xD;
      of different gestational age groups,the investigators should focus on the study of premature&#xD;
      infants cases.Due to less relevant research for using PS treatment to cure newborn RDS in&#xD;
      high altitude area,this retrospective study conducts statistics and analysis of recently&#xD;
      three-year cases in some hospital of high altitude area,to explore the treatment effect of&#xD;
      the high altitude region and the impact of altitude on the treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      in order to explore feasibility and efficacy for PS treatment of newborn RDS in high-altitude&#xD;
      area ,and its efficacy at different altitudes, the investigators conduct a multi-center&#xD;
      retrospective study of RDS cases in Qinghai and Tibet these two high-altitude area,and use&#xD;
      RDS cases under the unique conditions to do statistics and analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>bronchopulmonary dysplasia(BPD)</measure>
    <time_frame>before discharge or 36 weeks' gestational age</time_frame>
    <description>the incidence of BPD in infants with neonatal neonatal RDS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>before discharge or 36 weeks' gestational age</time_frame>
    <description>the incidence of BPD in infants with neonatal RDS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraventriclular hemorrhage(IVH)</measure>
    <time_frame>before discharge or 36 weeks' gestational age</time_frame>
    <description>the incidence of IVH in infants with neonatal RDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>necrotizing enterocolitis(NEC)</measure>
    <time_frame>before discharge or 36 weeks' gestational age</time_frame>
    <description>the incidence of NEC in infants with neonatal RDS</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Surfactant</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>surfactant</intervention_name>
    <description>surfactant is given when neonatal respiratory distress syndrome is diagnosed</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        the preterm infants less than 37 weeks and diagnosed with NRDS were included in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  the preterm infants less than 37 weeks were included in the study;diagnosed with NRDS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  parents' rejecting to join;major congenital abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Day</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ma Juan, MD</last_name>
    <phone>13508300283</phone>
    <email>petshi530@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen Long, PhD,MD</last_name>
    <phone>13883559467</phone>
    <email>476679422@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatrics, Daping Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Ma, physician</last_name>
      <phone>18680887330</phone>
      <email>zoe330@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 18, 2018</study_first_submitted>
  <study_first_submitted_qc>March 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>February 14, 2021</last_update_submitted>
  <last_update_submitted_qc>February 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Ma Juan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Hyaline Membrane Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

